A human genome editing-based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features.

Autor:	Bueno C; Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain.; Spanish Collaborative Cancer Network, Carlos III Health Institute, Barcelona, Spain., Torres-Ruiz R; Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain.; Advanced Therapies Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.; Molecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain., Velasco-Hernandez T; Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain., Molina O; Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain., Petazzi P; Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain., Martinez A; Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain., Rodriguez V; Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain., Vinyoles M; Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain., Cantilena S; Development Biology Cancer Program, Cancer Section, UCLGOS Institute of Child Health, London, United Kingdom., Williams O; Development Biology Cancer Program, Cancer Section, UCLGOS Institute of Child Health, London, United Kingdom., Vega-Garcia N; Hematology Laboratory, Hospital Sant Joan de Déu Barcelona, Barcelona, Spain.; Developmental Tumors Biology Group, Leukemia, and other Pediatric Hemopathies, Pediatric Cancer Center Barcelona, Institut de Recerca, Hospital Sant Joan de Déu, Barcelona, Spain., Rodriguez-Perales S; Molecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain., Segovia JC; Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain.; Advanced Therapies Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain., Quintana-Bustamante O; Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain.; Advanced Therapies Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain., Roy A; MRC Molecular Hematology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford Biomedical Research Center Hematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.; Department of Pediatrics and National Institute for Health and Care Research Oxford Biomedical Research Centre Hematology Theme, University of Oxford, Oxford, United Kingdom., Meyer C; Diagnostic Center of Acute Leukemia-Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany., Marschalek R; Diagnostic Center of Acute Leukemia-Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany., Smith AL; MRC Molecular Hematology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford Biomedical Research Center Hematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom., Milne TA; MRC Molecular Hematology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford Biomedical Research Center Hematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom., Fraga MF; Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.; Cancer Epigenetics and Nanomedicine Laboratory, Nanomaterials and Nanotechnology Research Center, El Entrego, Spain.; Health Research Institute of Asturias, Institute of Oncology of Asturias and Department of Organisms and Systems Biology, University of Oviedo, Oviedo, Spain., Tejedor JR; Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.; Cancer Epigenetics and Nanomedicine Laboratory, Nanomaterials and Nanotechnology Research Center, El Entrego, Spain.; Health Research Institute of Asturias, Institute of Oncology of Asturias and Department of Organisms and Systems Biology, University of Oviedo, Oviedo, Spain., Menéndez P; Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain.; Spanish Collaborative Cancer Network, Carlos III Health Institute, Barcelona, Spain.; Department of Biomedicine, University of Barcelona, Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	Blood [Blood] 2023 Nov 16; Vol. 142 (20), pp. 1752-1756.
DOI:	10.1182/blood.2023020858
Abstrakt:	Cellular ontogeny and MLL breakpoint site influence the capacity of MLL-edited CD34+ hematopoietic cells to initiate and recapitulate infant patients' features in pro-B-cell acute lymphoblastic leukemia (B-ALL). We provide key insights into the leukemogenic determinants of MLL-AF4+ infant B-ALL. (© 2023 by The American Society of Hematology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu